Scientific Meeting

Getting to Zero: What will it take?
Annual National CFAR Scientific Meeting
Thursday, November 3rd, 2016
Joseph B. Martin Conference Center Auditorium

Harvard Medical School
77 Avenue Louis Pasteur, Boston, MA 02115 

The 20th Annual National CFAR Scientific Meeting will be devoted to examining the most up-to-date information available on HIV treatment and ARV demand, HIV vaccine development, and HIV cure.  The day will be structured over four panels featuring senior HIV investigators, early career investigator presentations, and panel discussions.  Register now for "Getting to Zero: What will it take?"

View the Speakers' Biographies

 

Meeting Agenda

7:45 AM – BREAKFAST

8:45 AM – WELCOME: Bruce D. Walker

8:50 AM – OPEN PLENARY: Addressing HIV Persistence: A Novel Approach Involving α4β7 Integrin – Anthony S. Fauci

Panel I: Antiretrovirals as Prevention: What will it take to have population-level impact?
Moderators: Carl W. Dieffenbach; Doug S. Kwon
Panel Discussants: Kenneth H. Mayer; Sharon L. Hillier; Raphael J. Landovitz, Kenneth A. Freedberg

9:30 AM – ORAL PRESENTATIONS:

1. Douglas S. Krakower: Oral PrEP: How well is it working and where will it take us?
2. Brenda Gati Mirembe: Dapivirine vaginal ring: promise and limitations
3. David Goodman-Meza: Implications for long acting injectables
4. Scott Dryden-Peterson: Botswana Combination Prevention Project: How close to zero will HIV treatment get us?

10:30 AM – PANEL I DISCUSSION

11:00 AM – BREAK

Panel II: From Recommendations to Reality in our quest to sustain HIV treatment for all
Moderators: Susan Cu-Uvin; Maureen M. Goodenow
Panel Discussants: Susan P. Buchbinder; Conall M. O’Cleirigh, Kevin Cranston

11:15 AM – ORAL PRESENTATIONS:

1. Bisola O. Ojikutu: Beyond the Basics: Getting to Zero in the Black Community in the US [Results from the National Survey on HIV in the Black Community (NSHBC)]
2. Hyman Scott: Determining HIV acquisition risk factors to better target prevention modalities
3. Abigail Batchelder: Developing socio-behavioral interventions to address HIV-related health-related behavior change

12:00 PM – PANEL II DISCUSSION

12:30 PM – LUNCH

Panel III: The state of HIV vaccine efforts and antibody-mediated treatment- how much longer until we have an effective HIV Vaccine?
Moderators: Bruce D. Walker; Boris D. Juelg
Panel Discussants: Dan Barouch; Galit Alter; William Schief

1:30 PM – ORAL PRESENTATIONS:

1. Kathryn E. Stephenson: Novel adenoviral based vaccine development for HIV
2. Johannes F. Scheid: Antibody mediated therapy
3. Jon Steichen: Reductionist vaccine design strategies to induce broadly neutralizing antibodies against HIV

2:15 PM – PANEL III DISCUSSION

2:45 PM – BREAK

Panel IV: HIV Cure: What do we know and how do we get there?
Moderators: Daniel R. Kuritzkes; Athe M. Tsibris
Panel Discussants: John W. Mellors; Mathias D. Lichterfeld; James B. Whitney; Deborah Persaud 

3:00 PM – ORAL PRESENTATIONS:

1. Guinevere Q. Lee: HIV persistence in T cell subsets
2. So-Yon Lim: NHP modeling of the HIV reservoir
3. John Bui: Shock and Kill or Excite and Expand: Rethinking HIV Cure Strategies

3:45 PM – PANEL IV DISCUSSION

4:15 PM – CLOSING PLENARY: How to Create Demand at a time of Increased ART availability  Ambassador-at-Large, Deborah L. Birx